ProMIS Neurosciences Inc (PMN) Actualités

ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally...

ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference

Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for...

Form 8-K - Current report

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities